Literature DB >> 25865438

A Weibull multi-state model for the dependence of progression-free survival and overall survival.

Yimei Li1,2, Qiang Zhang1,3.   

Abstract

In oncology clinical trials, overall survival, time to progression, and progression-free survival are three commonly used endpoints. Empirical correlations among them have been published for different cancers, but statistical models describing the dependence structures are limited. Recently, Fleischer et al. proposed a statistical model that is mathematically tractable and shows some flexibility to describe the dependencies in a realistic way, based on the assumption of exponential distributions. This paper aims to extend their model to the more flexible Weibull distribution. We derived theoretical correlations among different survival outcomes, as well as the distribution of overall survival induced by the model. Model parameters were estimated by the maximum likelihood method and the goodness of fit was assessed by plotting estimated versus observed survival curves for overall survival. We applied the method to three cancer clinical trials. In the non-small-cell lung cancer trial, both the exponential and the Weibull models provided an adequate fit to the data, and the estimated correlations were very similar under both models. In the prostate cancer trial and the laryngeal cancer trial, the Weibull model exhibited advantages over the exponential model and yielded larger estimated correlations. Simulations suggested that the proposed Weibull model is robust for data generated from a range of distributions.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Weibull distribution; correlation; oncology; overall survival; progression-free survival

Mesh:

Year:  2015        PMID: 25865438      PMCID: PMC4490073          DOI: 10.1002/sim.6501

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  13 in total

Review 1.  Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

Authors:  Patricia A Tang; Søren M Bentzen; Eric X Chen; Lillian L Siu
Journal:  J Clin Oncol       Date:  2007-09-17       Impact factor: 44.544

Review 2.  Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments.

Authors:  Pascal Piedbois; Marc Buyse
Journal:  Curr Opin Oncol       Date:  2008-07       Impact factor: 3.645

3.  A statistical model for the dependence between progression-free survival and overall survival.

Authors:  Frank Fleischer; Birgit Gaschler-Markefski; Erich Bluhmki
Journal:  Stat Med       Date:  2009-09-20       Impact factor: 2.373

Review 4.  Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design.

Authors:  F A Eskens; J Verweij
Journal:  Crit Rev Oncol Hematol       Date:  2000-05       Impact factor: 6.312

Review 5.  In the end what matters most? A review of clinical endpoints in advanced breast cancer.

Authors:  Sunil Verma; Deanna McLeod; Gerald Batist; André Robidoux; Ilídio R S Martins; John R Mackey
Journal:  Oncologist       Date:  2011-01-06

6.  Progression-free survival as a surrogate endpoint in advanced breast cancer.

Authors:  Rebecca A Miksad; Vera Zietemann; Raffaella Gothe; Ruth Schwarzer; Annette Conrads-Frank; Petra Schnell-Inderst; Björn Stollenwerk; Uwe Siebert
Journal:  Int J Technol Assess Health Care       Date:  2008       Impact factor: 2.188

7.  Progression-free survival is a surrogate for survival in advanced colorectal cancer.

Authors:  Marc Buyse; Tomasz Burzykowski; Kevin Carroll; Stefan Michiels; Daniel J Sargent; Langdon L Miller; Gary L Elfring; Jean-Pierre Pignon; Pascal Piedbois
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

Review 8.  Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.

Authors:  Cornelis J A Punt; Marc Buyse; Claus-Henning Köhne; Peter Hohenberger; Roberto Labianca; Hans J Schmoll; Lars Påhlman; Alberto Sobrero; Jean-Yves Douillard
Journal:  J Natl Cancer Inst       Date:  2007-06-27       Impact factor: 13.506

9.  Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.

Authors:  M Roach; M DeSilvio; C Lawton; V Uhl; M Machtay; M J Seider; M Rotman; C Jones; S O Asbell; R K Valicenti; S Han; C R Thomas; W S Shipley
Journal:  J Clin Oncol       Date:  2003-05-15       Impact factor: 44.544

Review 10.  Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer.

Authors:  B Sherrill; M Amonkar; Y Wu; C Hirst; S Stein; M Walker; J Cuzick
Journal:  Br J Cancer       Date:  2008-10-28       Impact factor: 7.640

View more
  6 in total

1.  Randomized phase II/III confirmatory treatment selection design with a change of survival end points: Statistical design of Radiation Therapy Oncology Group 1216.

Authors:  Qiang Ed Zhang; Qian Wu; Paul M Harari; David I Rosenthal
Journal:  Head Neck       Date:  2018-12-14       Impact factor: 3.147

2.  Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial.

Authors:  Li Li; Qingqing Zhuang; Zeyi Cao; Rutie Yin; Yaping Zhu; Lirong Zhu; Xing Xie; Youzhong Zhang; Li Li; Qiang Wu; Jianhua Zheng; Qi Zhou; Xiaoping Li; Lingying Wu; Youji Feng; Changyu Wang
Journal:  Oncol Lett       Date:  2018-01-10       Impact factor: 2.967

3.  Quantifying the association between progression-free survival and overall survival in oncology trials using Kendall's τ.

Authors:  Enya M Weber; Andrew C Titman
Journal:  Stat Med       Date:  2018-10-12       Impact factor: 2.373

4.  Bootstrapping complex time-to-event data without individual patient data, with a view toward time-dependent exposures.

Authors:  Tobias Bluhmki; Hein Putter; Arthur Allignol; Jan Beyersmann
Journal:  Stat Med       Date:  2019-06-04       Impact factor: 2.373

5.  Nonparametric analysis of nonhomogeneous multistate processes with clustered observations.

Authors:  Giorgos Bakoyannis
Journal:  Biometrics       Date:  2020-07-21       Impact factor: 2.571

6.  Detection of Rare Mutations in EGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger Sequencing.

Authors:  Chaoyue Liang; Zhuolin Wu; Xiaohong Gan; Yuanbin Liu; You You; Chenxian Liu; Chengzhi Zhou; Ying Liang; Haiyun Mo; Allen M Chen; Jiexia Zhang
Journal:  Yonsei Med J       Date:  2018-01       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.